Intervention Review

You have free access to this content

Neuroprotection for treatment of glaucoma in adults

  1. Dayse F Sena1,*,
  2. Kristina Lindsley2

Editorial Group: Cochrane Eyes and Vision Group

Published Online: 28 FEB 2013

Assessed as up-to-date: 16 OCT 2012

DOI: 10.1002/14651858.CD006539.pub3


How to Cite

Sena DF, Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No.: CD006539. DOI: 10.1002/14651858.CD006539.pub3.

Author Information

  1. 1

    Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA

  2. 2

    Johns Hopkins Bloomberg School of Public Health, Department of Epidemiology, Baltimore, Maryland, USA

*Dayse F Sena, Massachusetts Eye and Ear Infirmary, 243 Charles St, Connecting Building 703, Boston, Massachusetts, 02114, USA. sena.dayse@gmail.com. sena.dayse@gmail.com.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 28 FEB 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
LoGTS 2011 {published data only}
  • Garudadri CS, Choudhari NS, Rao HL, Senthil S. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-pressure Glaucoma Treatment Study. American Journal of Ophthalmology 2011;152(5):877-8.
  • Krupin T. A clinical trial studying neuroprotection in low-pressure glaucoma. Eye 2007;21(Suppl 1):S51-4.
  • Krupin T. Special considerations in low-tension glaucoma. Canadian Journal of Ophthalmology 2007;42(3):414-7.
  • Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S, Low-Pressure Glaucoma Study Group. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. American Journal of Ophthalmology 2011;151(4):671-81.
  • Krupin T, Liebmann JM, Greenfield DS, Rosenberg LF, Ritch R, Yang JW. The Low-pressure Glaucoma Treatment Study (LoGTS) study design and baseline characteristics of enrolled patients. Ophthalmology 2005;112(3):376-85.
  • Quaranta L, Floriani I. The rate of progression and ocular perfusion pressure in the Low-pressure Glaucoma Treatment Study. American Journal of Ophthalmology 2011;152(5):880-1.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Alm 2004 {published data only}
Anderson 2003 {published data only}
  • Anderson DR, Drance SM, Schulzer M. The Collaborative Normal-Tension Glaucoma Study Group. Factors that predict the benefit of lowering intraocular pressure in normal tension glaucoma. American Journal of Ophthalmology 2003;136(5):820-9.
Araie 2010 {published data only}
  • Araie M, Shirato S, Yamazaki Y, Kitazawa Y, Ohashi Y, Nipradilol-Timolol Study Group. Visual field loss in patients with normal-tension glaucoma under topical nipradilol or timolol: subgroup and subfield analyses of the nipradilol-timolol study. Japanese Journal of Ophthalmology 2010;54(4):278-85.
Araie 2011a {published data only}
  • Araie M. Basic and clinical studies of pressure-independent damaging factors of open angle glaucoma. Nippon Ganka Gakkai Zasshi 2011;115(3):213-36.
Araie 2011b {published data only}
Blumenthal 2001 {published data only}
  • Blumenthal EZ, Weinreb RN. Assessment of the retinal nerve fiber layer in clinical trials of glaucoma neuroprotection. Survey of Ophthalmology 2001;45(Suppl 3):S305-12.
Cantor 1997 {published data only}
  • Cantor LB, Burke J. Brimonidine. Expert Opinion on Investigational Drugs 1997;6(8):1063-83.
Cellini 1999 {published data only}
  • Cellini M, Rossi A, Moretti M. The use of polyunsaturated fatty acids in ocular hypertension. A study with blue-on-yellow perimetry. Acta Ophthalmologica Scandinavica Supplement 1999;77(229):54-5.
Chader 2012 {published data only}
Changhua 2003 {published data only}
  • Changhua Y, Youqin J. A clinical study of the neuroprotection effect of Erigeron Breviscapus Hand-Mazz on glaucomatous patient eyes. Chinese Ophthalmic Research 2003;21(3):307-11.
Chen 2006 {published data only}
  • Chen CL, Tseng HY, Wu KY. Rescula as an alternative therapy for beta-blockers with long-term drift effect in glaucoma patients. Kaohsiung Journal of Medical Sciences 2006;22(6):266-70.
Cho 2010 {published data only}
  • Cho SW, Kim JM, Park KH, Choi CY. Effects of brimonidine 0.2%-timolol 0.5% fixed-combination therapy for glaucoma. Japanese Journal of Ophthalmology 2010;54(5):407-13.
CNTGS 1998 {published data only}
  • Anderson DR, Drance SM, Schulzer M, Collaborative Normal-Tension Glaucoma Study Group. Natural history of normal-tension glaucoma. Ophthalmology 2001;108(2):247-53.
  • Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. American Journal of Ophthalmology 1998;126(4):487-97.
  • Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. American Journal of Ophthalmology 1998;126(4):498-505.
Cohen 2005 {published data only}
  • Cohen JS, Khatana AK, Greff LJ. Evolving paradigms in the medical treatment of glaucoma. International Ophthalmology 2005;25(5-6):253-65.
Cordeiro 2011 {published data only}
Danesh-Meyer 2011 {published data only}
Drance 1998 {published data only}
EMGT 2002 {published data only}
  • Erb C. Early Manifest Glaucoma Trial update 2004. Der Ophthalmologe 2005;102(3):219-21.
  • Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Archives of Ophthalmology 2002;120(10):1268-79.
  • Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E, et al. Factors for glaucoma progression and the effect of treatment. Archives of Ophthalmology 2003;121(1):48-56.
Evans 2003 {published data only}
  • Bartlett JD, Evans DW. Contrast sensitivity improvements in brimonidine-treated primary open-angle glaucoma patients suggest a neuroprotective mechanism. Investigative Ophthalmology and Visual Science 2002; Vol. 43:ARVO E-abstract 2201.
  • Evans DW, Hosking SL, Gherghel D, Bartlett JD. Contrast sensitivity improves after brimonidine therapy in primary open angle glaucoma: a case for neuroprotection. British Journal of Ophthalmology 2003;87(12):1463-5.
Frolov 2011 {published data only}
  • Frolov MA, Gonchar PA, Barashkov VI, Kumar V, Morozova NS, Frolov AM, et al. The effect of parenteral citicoline on visual functions and life quality of patients with primary open-angle glaucoma. Vestnik Oftalmologii 2011;127(5):18-21.
Gandolfi 2004 {published data only}
  • Gandolfi SA, Sangermani C, Cimino L, Ungaro N, Tardini M, Viswanathan A, et al. Is there a non IOP-related effect of brimonidine on visual field progression in human glaucoma?. Investigative Ophthalmology and Visual Science 2004; Vol. 45:ARVO E-abstract 2298.
Garcia-Medina 2011 {published data only}
  • Garcia-Medina JJ, Garcia-Medina M, Garrido-Fernandez P, Galvan-Espinosa J. A 2-year follow-up of antioxidant supplementation in primary open-angle glaucoma. Ophthalmic Research. Conference: SIRCOVA-ARVO Congress 2011. Valencia, Spain 2011.
Ge 2008 {published data only}
  • Ge J. Glaucoma neuroprotection--how far is it from a dream to reality. Chung-Hua Yen Ko Tsa Chih - Chinese Journal of Ophthalmology 2008;44(5):385-7.
Harris 1995 {published data only}
  • Harris A, Spaeth GL, Sergott RC, Katz LJ, Cantor LB, Martin BJ. Retrobulbar arterial hemodynamic effects of betaxolol and timolol in normal-tension glaucoma. American Journal of Ophthalmology 1995;120(2):168-75.
Harris 1999 {published data only}
  • Harris A, Arend O, Kagemann L, Garrett M, Chung HS, Martin B. Dorzolamide, visual function and ocular hemodynamics in normal-tension glaucoma. Journal of Ocular Pharmacology and Therapeutics 1999;15(3):189-97.
Hoyng 2002 {published data only}
Iester 2004 {published data only}
  • Iester M, Perdicchi A, Venturino G, Rolando M, Traverso, CE, Leonardi E, et al. Short-term effects of Bimatoprost in glaucoma patients from an outpatient clinic. Journal of Ocular Pharmacology and Therapeutics 2004;20(5):393-400.
Inan 2003 {published data only}
Kass 1989 {published data only}
  • Kass MA. Timolol treatment prevents or delays glaucomatous visual field loss in individuals with ocular hypertension: a five-year, randomized, double-masked, clinical trial. Transactions of the American Ophthalmological Society 1989;87:598-618.
Kjellgren 1995 {published data only}
  • Kjellgren D, Douglas G, Mikelberg FS, Drance SM, Alm A. The short-time effect of latanoprost on the intraocular pressure in normal pressure glaucoma. Acta Ophthalmologica Scandinavica 1995;73(3):233-6.
Koseki 1999 {published data only}
  • Koseki N, Araie M, Yamagami J, Shirato S, Yamamoto S. Effects of oral brovincamine on visual field damage in patients with normal-tension glaucoma with low-normal intraocular pressure. Journal of Glaucoma 1999;8(2):117-23.
Liu 2002 {published data only}
  • Liu CJ, Ko YC, Cheng CY, Chiu AW, Chou JC, Hsu WM, et al. Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients. Ophthalmology 2002;109(12):2241-7.
Mastropasqua 1998 {published data only}
  • Mastropasqua L, Ciancaglini M, Carpineto P, Verdesca G, Ciafre M, Costagliola C. The effect of 1% apraclonidine on visual field parameters in patients with glaucoma and ocular hypertension. Annals of Ophthalmology-Glaucoma 1998;30(1):41-5.
McCarty 2003 {published data only}
O'Donoghue 2000 {published data only}
  • O'Donoghue EP. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomised study. Ireland Latanoprost Study Group. British Journal of Ophthalmology 2000;84(6):579-82.
Park 2011 {published data only}
  • Park JW, Kwon HJ, Chung WS, Kim CY, Seong GJ. Short-term effects of Ginkgo biloba extract on peripapillary retinal blood flow in normal tension glaucoma. Korean Journal of Ophthalmology 2011;25(5):323-8.
Pfeiffer 2002 {published data only}
Robin 1993 {published data only}
  • Robin AL. Effect of topical apraclonidine on the frequency of intraocular pressure elevations after combined extracapsular cataract extraction and trabeculectomy. Ophthalmology 1993;100(5):628-33.
Rulo 1996 {published data only}
  • Rulo AH, Greve EL, Geijssen HC, Hoyng PF. Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma. Ophthalmology 1996;103(8):1276-82.
Sawada 1996 {published data only}
  • Sawada A, Kitazawa Y, Yamamoto T, Okabe I, Ichien K. Prevention of visual field defect progression with Brovincamine in eyes with normal-tension glaucoma. Ophthalmology 1996;103(2):283-8.
Wang 2010 {published data only}
  • Wang Y, Qiu B, Zhang CX, Ou Y, Pang L, Li Z. Neuro-protective effects of yiyanming solution on visual function of glaucoma patient. Chinese Ophthalmic Research 2010;28(11):1087-90.

References to studies awaiting assessment

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
NCT00141882 {unpublished data only}
  • NCT00141882. Memantine in patients With chronic glaucoma. clinicaltrials.gov/ct2/show/NCT00141882 (accessed 13 November 2009 and 12 January 2012).
NCT00168350 {unpublished data only}
  • NCT00168350. Memantine in patients with chronic glaucoma. clinicaltrials.gov/ct2/show/NCT00168350 (accessed 13 November 2009 and 12 January 2012).

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
AAO Preferred Practice Pattern
  • American Academy of Ophthalmology. Primary open-angle glaucoma, preferred practice pattern. San Francisco: American Academy of Ophthalmology, 2005. Available at: www.aao.org/ppp.
AGIS 1994
  • Advanced Glaucoma Intervention Study. 2. Visual field test scoring and reliability. Ophthalmology 1994;101(8):1445-55.
Armaly 1980
  • Armaly MF, Krueger DE, Maunder L, Becker B, Hetherington J Jr, Kolker AE, et al. Biostatistical analysis of the collaborative glaucoma study. I. Summary report of the risk factors for glaucomatous visual-field defects. Archives of Ophthalmology 1980;98(12):2163-71.
Bathija 1998
  • Bathija R, Gupta N, Zangwill L, Weinreb RN. Changing definition of glaucoma. Journal of Glaucoma 1998;7(3):165-9.
Bonomi 2002
Brubaker 1996
Cheung 2008
  • Cheung W, Guo L, Cordeiro MF. Neuroprotection in glaucoma: drug-based approaches. Optometry and Vision Science 2008;85(6):406-16.
Cockburn 1983
  • Cockburn DM. Does reduction of intraocular pressure (IOP) prevent visual field loss in glaucoma?. American Journal of Optometry and Physiological Optics 1983;60(8):705-11.
Csaky 2008
  • Csaky KG, Richman EA, Ferris FL 3rd. Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium. Investigative Ophthalmology and Visual Science 2008;49(2):479-89.
Danesh-Meyer 2009
Deeks 2011
  • Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Fan 2010
  • Fan BJ, Figuieredo Sena DR, Pasquale LR, Grosskreutz CL, Rhee DJ, Chen TC, et al. Lack of association of polymorphisms in elastin with pseudoexfoliation syndrome and glaucoma. Journal of Glaucoma 2010;19(7):432-6.
Feke 2008
Foster 2000
Friedman 2004
  • Friedman DS, Wolfs RC, O'Colmain BJ, Klein BE, Taylor HR, West S, et al. Prevalence of open-angle glaucoma among adults in the Unites States. Archives of Ophthalmology 2004;122(4):532-8.
Garway-Heath 1998
  • Garway-Heath DF, Ruben ST, Viswanathan A, Hitchings RA. Vertical cup/disc ratio in relation to optic disc size: its value in the assessment of the glaucoma suspect. British Journal of Ophthalmology 1998;82(10):1118-24.
Glanville 2006
  • Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130-6.
Gupta 1997
  • Gupta N, Weinreb RN. New definitions of glaucoma. Current Opinion in Ophthalmology 1997;8(2):38-41.
Hare 2009
  • Hare WA, Wheeler L. Experimental glutamatergic excitotoxicity in rabbit retinal ganglion cells: block by memantine. Investigative Ophthalmology and Visual Science 2009;50(6):2940-8.
Hauser 2006a
  • Hauser MA, Allingham RR, Linkroum K, Wang J, LaRocque-Abramson K, Figueiredo D, et al. Distribution of WDR36 DNA sequence variants in patients with primary open-angle glaucoma. Investigative Ophthalmology and Visual Science 2006;47(6):2542-6.
Hauser 2006b
  • Hauser MA, Sena DF, Flor J, Walter J, Auguste J, Larocque-Abramson K, et al. Distribution of optineurin sequence variations in an ethnically diverse population of low-tension glaucoma patients from the United States. Journal of Glaucoma 2006;15(5):358-63.
Heijl 2002
  • Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Archives of Ophthalmology 2002;120(10):1268-79.
Higgins 2011
  • Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Hunter 2005
Ju 2009
  • Ju WK, Kim KY, Angert M, Duong-Polk KX, Lindsey JD, Ellisman MH, et al. Memantine blocks mitochondrial OPA1 and cytochrome c release and subsequent apoptotic cell death in glaucomatous retina. Investigative Ophthalmology and Visual Science 2009;50(2):707-16.
Kamal 1998
Levin 1999
Levin 2008
  • Levin LA, Peeples P. History of neuroprotection and rationale as a therapy for glaucoma. American Journal of Managed Care 2008;14(1 Suppl):S11-4.
Lipton 2003
McKinnon 2008
  • McKinnon SJ, Goldberg LD, Peeples P, Walt JG, Bramley TJ. Current management of glaucoma and the need for complete therapy. American Journal of Managed Care 2008;14(1 Suppl):S20-7.
Neacsu 2003
  • Neacsu A, Oprean C, Curea M, Tuchila G, Trifu M. Neuroprotection with carotenoids in glaucoma. Oftalmologia 2003;59(4):70-5.
Neufeld 1997
  • Neufeld AH, Hernandez MR, Gonzalez M. Nitric oxide synthase in the human glaucomatous optic nerve head. Archives of Ophthalmology 1997;115(4):497-503.
Neufeld 1998
  • Neufeld AH. New conceptual approaches for pharmacological neuroprotection in glaucomatous neuronal degeneration. Journal of Glaucoma 1998;7(6):434-8.
NICE Guidelines
  • National Collaborating Centre for Acute Care. Glaucoma: Diagnosis and management of chronic open angle glaucoma and ocular hypertension. National Institute for Health and Clinical Excellence guideline April 2009. http://www.nice.org.uk [accessed Nov 2009].
Nouri-Mahdavi 2004
  • Nouri-Mahdavi K, Hoffman D, Coleman AL, Liu G, Li G, Gaasterland D, et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology 2004;111(9):1627-35.
Osborne 2003
  • Osborne NN, Chidlow G, Wood J, Casson R. Some current ideas on the pathogenesis and the role of neuroprotection in glaucomatous optic neuropathy. European Journal of Ophthalmology 2003;13(Suppl 3):S19-26.
Osborne 2009
Quigley 1999
Quigley 2001
  • Quigley HA, West SK, Rodriguez J, Munoz B, Klein R, Snyder R. The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER. Archives of Ophthalmology 2001;119(12):1819-26.
Quigley 2006
Quigley 2012
Ramakrishnan 2003
  • Ramakrishnan R, Nirmalan PK, Krishnadas R, Thulasiraj RD, Tielsch JM, Katz J, et al. Glaucoma in a rural population of southern India: the Aravind comprehensive eye survey. Ophthalmology 2003;110(8):1484-90.
Resnikoff 2004
  • Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, et al. Global data on visual impairment in the year 2002. Bulletin of the World Health Organization 2004;82(11):844-51.
RevMan 2011
  • The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
Schwartz 1996
  • Schwartz M, Belkin M, Yoles E, Solomon A. Potential treatment modalities for glaucomatous neuropathy: neuroprotection and neuroregeneration. Journal of Glaucoma 1996;5(6):427-32.
Schwartz 2000
  • Schwartz M, Yoles E. Neuroprotection: a new treatment modality for glaucoma?. Current Opinion in Ophthalmology 2000;11(2):107-11.
Seong 2009
  • Seong GJ, Rho SH, Kim CS, Moon JI, Kook MS, Kim YY, et al. Potential benefit of intraocular pressure reduction in normal-tension glaucoma in South Korea. Journal of Ocular Pharmacology & Therapeutics 2009;25(1):91-6.
Shields 1996
  • Shields MB, Ritch R, Krupin T. Classification of the glaucomas. In: Ritch R, Shields MB, Krupin T editor(s). The glaucomas. 2nd Edition. St. Louis: Mosby, 1996.
Tielsch 1991
  • Tielsch JM, Sommer A, Katz J, Royall RM, Quigley HA, Javitt J. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. Journal of the American Medical Association 1991;266(3):369-74.
Vass 2007
  • C Vass, C Hirn, T Sycha, O Findl, S Sacu, P Bauer, L Schmetterer. Medical interventions for primary open angle glaucoma and ocular hypertension. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD003167.pub3]
Weinreb 1999
  • Weinreb RN, Levin LA. Is neuroprotection a viable therapy for glaucoma?. Archives of Ophthalmology 1998;117(11):1540-4.
Zhong 2007
  • Zhong L, Bradley J, Schubert W, Ahmed E, Adamis AP, Shima DT, et al. Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice. Investigative Ophthalmology and Visual Science 2007;48(3):1212-8.

References to other published versions of this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. Additional references
  5. References to other published versions of this review
Sena 2010